Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor

(2018) Marie-Pierre Collin et al.   ChemMedChem

Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer

(2018) Katarzyna Starska et al.   CELLULAR ONCOLOGY

FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression

(2018) Xiangdong Zhao et al.   MOLECULAR CARCINOGENESIS

Fibroblast growth factor receptors as treatment targets in clinical oncology

(2018) Masaru Katoh   Nature Reviews Clinical Oncology

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

(2017) Timothy P.S. Perera et al.   MOLECULAR CANCER THERAPEUTICS

Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope

(2016) Rafael Morales-Barrera et al.   CANCER TREATMENT REVIEWS

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

(2016) K. Koole et al.   CLINICAL CANCER RESEARCH

FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

(2016) MASARU KATOH   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors

(2016) Joost C.M. Uitdehaag et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutics Targeting FGF Signaling Network in Human Diseases

(2016) Masaru Katoh   TRENDS IN PHARMACOLOGICAL SCIENCES

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers

(2015) F. Goke et al.   CLINICAL CANCER RESEARCH

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression

(2015) H Kotani et al.   ONCOGENE

The Fibroblast Growth Factor signaling pathway

(2015) David M. Ornitz et al.   Wiley Interdisciplinary Reviews-Developmental Biology

Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer

(2014) N Cihoric et al.   BRITISH JOURNAL OF CANCER

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

(2014) M. W. Wynes et al.   CLINICAL CANCER RESEARCH

FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

(2014) Anjili Mathur et al.   PLoS One

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

(2013) R. Dienstmann et al.   ANNALS OF ONCOLOGY

Essential role of AKT in tumor cells addicted to FGFR

(2013) Yi Hu et al.   ANTI-CANCER DRUGS

High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer

(2013) Matthias Preusser et al.   LUNG CANCER

Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck

(2013) Friederike Göke et al.   MODERN PATHOLOGY

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

(2013) K. M. Gust et al.   MOLECULAR CANCER THERAPEUTICS

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

(2012) Rebecca S. Heist et al.   Journal of Thoracic Oncology

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

(2010) E. M. Haugsten et al.   MOLECULAR CANCER RESEARCH

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer

(2009) D. C. Tomlinson et al.   CANCER RESEARCH

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY